Display options
Cite
Ellimuttil TM, Harrison K, Rollins AT, et al. Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev. 2021;7:e15doi: 10.15420/cfr.2021.07.
Ellimuttil, T. M., Harrison, K., Rollins, A. T., Feurer, I. D., Rega, S. A., Gray, J., & Menachem, J. N. (2021). Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Cardiac failure review, 7e15. https://doi.org/10.15420/cfr.2021.07
Ellimuttil, Tracey M, et al. "Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy." Cardiac failure review vol. 7 (2021): e15. doi: https://doi.org/10.15420/cfr.2021.07
Ellimuttil TM, Harrison K, Rollins AT, Feurer ID, Rega SA, Gray J, Menachem JN. Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. Card Fail Rev. 2021 Nov 12;7:e15. doi: 10.15420/cfr.2021.07. eCollection 2021 Mar. PMID: 34950505; PMCID: PMC8609416.
Copy Download .nbib Format: NLM
Share it on

Card Fail Rev. 2021 Nov 12;7:e15. doi: 10.15420/cfr.2021.07. eCollection 2021 Mar.

Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy.

Cardiac failure review

Tracey M Ellimuttil, Kimberly Harrison, Allman T Rollins, Irene D Feurer, Scott A Rega, Jennifer Gray, Jonathan N Menachem

Affiliations

  1. Department of Pharmacy, Vanderbilt University Medical Center Nashville, TN, US.
  2. Vanderbilt Transplant Center Nashville, TN, US.
  3. Division of Cardiovascular Medicine, Vanderbilt University Medical Center Nashville, TN, US.
  4. Department of Surgery, Vanderbilt University Medical Center Nashville, TN, US.
  5. Department of Biostatistics, Vanderbilt University Medical Center Nashville, TN, US.

PMID: 34950505 PMCID: PMC8609416 DOI: 10.15420/cfr.2021.07

[No abstract available.]

Copyright © 2021, Radcliffe Cardiology.

Keywords: 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor; Coronary allograft vasculopathy; heart transplantation complication

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare. Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasona

References

  1. J Am Coll Cardiol. 2001 Sep;38(3):814-8 - PubMed
  2. ESC Heart Fail. 2018 Dec;5(6):1118-1129 - PubMed
  3. Circulation. 2016 Nov 22;134(21):e468-e495 - PubMed
  4. Clin Pharmacol Ther. 2004 Aug;76(2):167-77 - PubMed
  5. Clin Transplant. 2018 May;32(5):e13248 - PubMed
  6. Circulation. 1987 Oct;76(4):827-34 - PubMed
  7. Curr Atheroscler Rep. 2000 May;2(3):208-17 - PubMed
  8. Circulation. 1997 Sep 2;96(5):1398-402 - PubMed
  9. Arch Intern Med. 2003 Mar 10;163(5):553-64 - PubMed
  10. Pharmacol Ther. 2003 Nov;100(2):141-56 - PubMed
  11. N Engl J Med. 1995 Sep 7;333(10):621-7 - PubMed
  12. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209 - PubMed
  13. Atherosclerosis. 1999 Aug;145(2):325-31 - PubMed
  14. J Biomed Inform. 2009 Apr;42(2):377-81 - PubMed
  15. Transplant Proc. 1999 Aug;31(5):2163-5 - PubMed
  16. Eur J Cardiothorac Surg. 1990;4(6):309-12; discussion 313 - PubMed
  17. Ann Pharmacother. 1995 Mar;29(3):235-9 - PubMed
  18. J Heart Lung Transplant. 2010 Jul;29(7):717-27 - PubMed
  19. J Heart Lung Transplant. 2014 Oct;33(10):996-1008 - PubMed
  20. Clin Transplant. 2019 Jan;33(1):e13454 - PubMed
  21. Clin Pharmacol Ther. 2006 Dec;80(6):565-81 - PubMed
  22. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934 - PubMed
  23. Am J Cardiol. 1994 Nov 15;74(10):1042-6 - PubMed
  24. ESC Heart Fail. 2020 Oct;7(5):2074-2081 - PubMed
  25. Lancet. 2010 Nov 13;376(9753):1670-81 - PubMed
  26. J Heart Lung Transplant. 2005 Nov;24(11):1736-40 - PubMed

Publication Types